A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms Neo-PREDICT-HER2
- 16 Sep 2019 Status changed from completed to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 24 Jun 2018 Status changed from discontinued to completed.